retatrutide diabetes trial Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 The retatrutide drug is manufactured
Description
GLP-1 medications reduce appetite and slow gastric emptying, which often creates a significant calorie deficit in the early weeks of treatment
Van Cauwenberghe et al
It is manageable through dietary adjustments and professional guidance

Do not ice immediately before injecting, as this can increase needle entry discomfort, but post injection cold application is helpful for some people

Tirzepatide delivers 20-22% average weight loss in clinical trials

Delivery Method The biggest difference is obvious: pills vs
